Microbiotix presents new data at the ASM Microbe 2018 Conference
Tags:
Seven presentations with data from multiple pipeline candidates including data from Microbiotix's innovative non-antibiotic programs targeting multi-drug resistant priority pathogens
WORCESTER, Mass., June 7, 2018 /PRNewswire/ -- Microbiotix, Inc., a clinical stage biotech company focused on the discovery and development of novel drugs that target serious infectious diseases and multi-drug resistant pathogens, announced today that it will make two oral presentations and five poster presentations covering its innovative programs targeting multi-drug resistant priority pathogens at the American Society of Microbiology (ASM) Microbe 2018 Conference, which is taking place June 7-11, 2018 in Atlanta, Georgia.
"Microbiotix is dedicated to supporting its pipeline of programs targeting the high unmet need caused by multi-drug resistant priority pathogens," said Terry Bowlin, PhD, President and CEO, Microbiotix. "We believe our innovative portfolio has great potential to help critically ill patients infected with several of today's most serious multi-drug resistant infectious agents."
Data will be presented on Microbiotix's T3SS (type III secretion system) inhibitor project, which was awarded $3.2 million from CARB-X (Combating Antibiotic-Resistant Bacteria Accelerator) in March 2017. The data will highlight evidence describing the novel molecular target of the Company's inhibitors of Type III Secretion in P. aeruginosa, which are being developed in collaboration with the UK's AMR Centre, a joint private-public initiative to support/accelerate the development of new antibiotics and diagnostics through a fully integrated development capability, offering translational RandD from pre-clinical hits through to clinical proof of concept.
Data will be presented on Microbiotix's novel RND efflux pump inhibitors, which target CRE (carbapenem-resistant enterobacteriaceae), a CDC and WHO high priority pathogen. An oral presentation and two posters will describe in vivo proof of principle and mechanistic studies.
An oral presentation and a poster will describe Microbiotix's anti-gonorrheal ribosomal rescue inhibitors, discovered in the broad spectrum Gram-negative/Gram-positive trans translation program.
Data will also be presented describing the activity of the aminospectinomycins against STD co-infections.
About Microbiotix, Inc.Microbiotix is a Worcester, MA-based biotech company focused on the discovery and development of novel drugs that target serious infectious diseases and multi-drug resistant pathogens. The Company's lead program, MBX-400, a novel, potent nucleoside dual DNA polymerase/kinase inhibitor for the management of cytomegalovirus (CMV) disease in transplant patients, is Phase 2-ready.
This press release was supported by the Cooperative Agreement Number IDSEP160030 from ASPR/BARDA and by an award from the Wellcome Trust, as administrated by CARB-X. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the HHS Office of the Assistant Secretary for Preparedness and Response, the National Institutes of Health or the Wellcome Trust.
Contact:
Microbiotix, Inc.
Terry Bowlin, Ph.D.
President and CEO
+1 (508) 757-2800
[email protected]
SOURCE Microbiotix, Inc.
http://www.microbiotix.com
Cision Distribution 888-776-0942
from 8 AM - 9 PM ET
